| Identification | Back Directory | [Name]
Benzenesulfonamide, N-(6-methoxy-3-pyridinyl)-3-nitro-4-[4-[(3-nitrophenyl)methyl]-1-piperazinyl]- | [CAS]
2911609-80-6 | [Synonyms]
| [Molecular Formula]
C23H24N6O7S | [MOL File]
2911609-80-6.mol | [Molecular Weight]
528.54 |
| Chemical Properties | Back Directory | [Boiling point ]
719.0±70.0 °C(Predicted) | [density ]
1.463±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
7.71±0.50(Predicted) | [color ]
Yellow to orange |
| Hazard Information | Back Directory | [Uses]
MyD88-IN-1 (Compound c17) is an orally active MyD88 inhibitor. MyD88-IN-1 inhibits the interaction of TLR4 and MyD88 and suppressed the NF-κB pathway. MyD88-IN-1 can be used in research of cancer and inflammatory[1]. | [in vivo]
MyD88-IN-1 (20 mg/kg, p.o., single dose) exhibits significant anti-inflammatory effects and alleviates lung tissue injury in the LPS (HY-D1056)-induced ALI mouse model[1]. | Animal Model: | LPS (HY-D1056)-induced acute lung injury (ALI) in C57BL/6L mice[1] | | Dosage: | 20 mg/kg | | Administration: | Oral gavage (p.o.), single dose, Administered 30 minutes before LPS induction | | Result: | Significantly reduced TNF-α and IL-6 levels in BALF and serum;
Decreased wet/dry lung ratio and total protein concentration;
Alleviated lung tissue histopathological changes. |
| [References]
[1] Chen P, et, al. Design, Synthesis, and Bioevaluation of Novel MyD88 Inhibitor c17 against Acute Lung Injury Derived from the Virtual Screen. J Med Chem. 2023 May 25;66(10):6938-6958. DOI:10.1021/acs.jmedchem.3c00359 |
|
|